Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting
July 27, 2016 16:05 ET
|
Karyopharm Therapeutics
- Oral Presentation Describing Efficacy of Selinexor in Gynecological Cancers - - Posters Highlighting Predictive Biomarkers of Selinexor Activity in Preclinical Models of Gynecological and...
Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published in Journal of Clinical Oncology
July 27, 2016 07:30 ET
|
Karyopharm Therapeutics
Data Provide Early Evidence of Anticancer Activity in Advanced Sarcoma and Inform Recommended Phase 2 Dose Company Also Announces Orphan Drug Designation Granted by FDA for Selinexor in Soft Tissue...
Karyopharm to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
July 06, 2016 07:30 ET
|
Karyopharm Therapeutics
NEWTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...
Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274
June 22, 2016 07:30 ET
|
Karyopharm Therapeutics
NEWTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1...
Karyopharm Outlines Key Selinexor Clinical Development Achievements
June 16, 2016 07:30 ET
|
Karyopharm Therapeutics
- Enrollment Complete in Phase 2b STORM Clinical Trial in Multiple Myeloma - - Patient Dosing Underway in Phase 1b Clinical Trial of Selinexor in Combination with Chemotherapeutic, Targeted and...
Karyopharm to Present at the 2016 JMP Securities Life Science Conference
June 15, 2016 07:30 ET
|
Karyopharm Therapeutics
NEWTON, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...
Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting
June 10, 2016 07:30 ET
|
Karyopharm Therapeutics
- Updated Clinical Data Shows High Response Rates When Selinexor Is Combined with Standard of Care Agents in Heavily Pretreated Patients with Multiple Myeloma - - Preclinical Data for...
Karyopharm to Present at the Jefferies 2016 Healthcare Conference
June 01, 2016 08:00 ET
|
Karyopharm Therapeutics
NEWTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer...
Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting
May 19, 2016 07:30 ET
|
Karyopharm Therapeutics
NEWTON, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an abstract describing preliminary...
Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual Meeting
May 18, 2016 17:40 ET
|
Karyopharm Therapeutics
NEWTON, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts involving selinexor...